Location:Home > Pharmaceutical
Product
Terazosin GMP Manufacturer Global Trade 63590-64-7 with Fast Delivery
- Molecular Formula: C19H25N5O4
- Molecular Weight: 387.439
- Appearance/Colour: white to off-white crystalline powder
- Melting Point: 281-283 °C
- Boiling Point: 664.5 °C at 760 mmHg
- PKA: pKa (0.1N NaOH): 7.1(at 25℃)
- Flash Point: 355.7 °C
- PSA: 103.04000
- Density: 1.332 g/cm3
- LogP: 1.64090
Terazosin(Cas 63590-64-7) Usage
|
Synthesis |
Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)- piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a tetrahydrofuryl radical. It is synthesized in exactly the same manner except using 1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51]. |
|
Drug interactions |
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Antidepressants: enhanced hypotensive effect with MAOIs. Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid concomitant use. Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Moxisylyte: possibly severe postural hypotension when used in combination. |
|
Metabolism |
Terazosin is metabolised in the liver; one of the metabolites has antihypertensive activity. Terazosin is excreted in faeces via the bile, and in the urine, as unchanged drug and metabolites. |
InChI:InChI=1/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2/p-1
63590-64-7 Relevant articles
A facile synthesis of [tetrahydrofuran-3H] terazosin
Egan, Judith A.,Souza, Steven M.,Filer, Crist N.
, p. 1881 - 1884 (2004)
An efficient synthesis of [3H] terazosin...
Targeting Influenza A Virus RNA Promoter
Bottini, Angel,De, Surya K.,Wu, Bainan,Tang, Changyan,Varani, Gabriele,Pellecchia, Maurizio
, p. 663 - 673 (2015/03/30)
The emergence of drug-resistant strains ...
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control ...
ANTIHYPERTENSIVE THERAPY
-
, (2009/09/08)
A new use of darusentan is provided in p...
Process for the preparation of terazosin hydrocloride dihydrate
-
Page/Page column 2; 3-4, (2008/06/13)
The present invention relates to an impr...
63590-64-7 Process route
-
-
943644-21-1
1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide
-
-
63590-64-7
terazosin
| Conditions | Yield |
|---|---|
|
With
ammonia;
In
water;
at 25 - 45 ℃;
for 1h;
pH=8.4;
|
-
-
23680-84-4
2-chloro-6,7-dimethoxyquinazolin-4-amine
-
-
63074-07-7
N-(tetrahydro-2-furoyl)-piperazine
-
-
63590-64-7
terazosin
| Conditions | Yield |
|---|---|
|
|
|
|
With
hydrogenchloride; potassium hydrogencarbonate;
In
methanol; 2-methoxy-ethanol;
|
63590-64-7 Upstream products
-
19237-84-4
prazosin hydrochloride
-
23680-84-4
2-chloro-6,7-dimethoxyquinazolin-4-amine
-
63074-07-7
N-(tetrahydro-2-furoyl)-piperazine
-
943644-21-1
1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide